Alnylam Pharmaceuticals (ALNY) Gross Profit (2018 - 2026)

Alnylam Pharmaceuticals' Gross Profit history runs 9 years deep, the most recent figure standing at $959.7 million for Q1 2026.

• Quarterly Gross Profit rose 83.14% year-over-year to $959.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 billion (up 71.39% YoY) and the FY2025 annual result came in at $3.0 billion, up 56.4% from the prior year.
• Gross Profit was $959.7 million for Q1 2026 at Alnylam Pharmaceuticals, up from $829.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $1.1 billion in Q3 2025 and bottomed at $189.8 million in Q1 2022.
• A 5-year average of $493.9 million and a median of $439.7 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit soared 194.58% — and 2024, when it sank 37.57%.
• Alnylam Pharmaceuticals' Gross Profit stood at $288.9 million in 2022, then advanced by 27.31% to $367.7 million in 2023, then jumped by 33.39% to $490.5 million in 2024, then soared by 69.07% to $829.3 million in 2025, then gained by 15.72% to $959.7 million in 2026.
• Business Quant data shows ALNY's Gross Profit at $959.7 million in Q1 2026, $829.3 million in Q4 2025, and $1.1 billion in Q3 2025.